Evidence map›Paper›PMID 41591762›Full record

ArticleThe Journal of cell biology2026

uPA-mediated remodeling of CCL21 gradients regulates lymphatic migration of dendritic cells.

Victor Collado-Diaz, Maria-Nefeli Christakopoulou, Philipp Schineis, Katharina Blatter, David Laubender, Sébastien Trzebanski, Marina Thoma, Yves Gadient, Hazal Tatliadim, Konstantinos Gkelis and 12 more

Abstract read
In one paragraph

Article in The Journal of cell biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Victor Collado-Diaz *Institute of Pharmaceutical Sciences, ETH Zurich , Zurich, Switzerland.ORCID 0000-0003-2981-4385
Maria-Nefeli Christakopoulou *Institute of Pharmaceutical Sciences, ETH Zurich , Zurich, Switzerland.ORCID 0000-0003-2950-917X
Philipp Schineis *Institute of Pharmaceutical Sciences, ETH Zurich , Zurich, Switzerland.ORCID 0000-0002-3579-503X
Katharina BlatterInstitute of Pharmaceutical Sciences, ETH Zurich , Zurich, Switzerland.ORCID 0009-0007-4363-1338
David LaubenderMax Planck Institute for Biological Intelligence , Martinsried, Germany.ORCID 0009-0005-8424-1657
Sébastien TrzebanskiInstitute of Pharmaceutical Sciences, ETH Zurich , Zurich, Switzerland.ORCID 0000-0002-0647-6814
Marina ThomaInstitute of Pharmaceutical Sciences, ETH Zurich , Zurich, Switzerland.ORCID 0009-0005-8263-4860
Yves GadientInstitute of Pharmaceutical Sciences, ETH Zurich , Zurich, Switzerland.ORCID 0009-0005-4281-9123
Hazal TatliadimInstitute of Pharmaceutical Sciences, ETH Zurich , Zurich, Switzerland.ORCID 0009-0007-7221-5704
Konstantinos GkelisInstitute of Pharmaceutical Sciences, ETH Zurich , Zurich, Switzerland.ORCID 0009-0007-1546-5248
Mona C FriessInstitute of Pharmaceutical Sciences, ETH Zurich , Zurich, Switzerland.ORCID 0000-0001-7212-1686
Vladimir PurvanovInstitute of Cell Biology and Immunology Thurgau (BITG) at the University of Konstanz , Kreuzlingen, Switzerland.ORCID 0009-0009-3939-9534
Guerric P B SamsonInstitute of Cell Biology and Immunology Thurgau (BITG) at the University of Konstanz , Kreuzlingen, Switzerland.ORCID 0000-0002-4505-6409
Marc ArtingerInstitute of Cell Biology and Immunology Thurgau (BITG) at the University of Konstanz , Kreuzlingen, Switzerland.ORCID 0009-0006-0487-5930
Radjesh BisoendialDepartment of Rheumatology and Clinical Immunology, Maasstad Hospital, Rotterdam, The Netherlands.ORCID 0000-0002-4041-3411
Manuel YepesDepartment of Neurology, Emory University, Atlanta, GA, USA.ORCID 0000-0002-5224-9663
Simon J de VeerInstitute for Molecular Bioscience, Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, The University of Queensland , Brisbane, Australia.ORCID 0000-0002-7041-9937
David CraikInstitute for Molecular Bioscience, Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, The University of Queensland , Brisbane, Australia.ORCID 0000-0003-0007-6796
Niels BehrendtFinsen Laboratory, Rigshospitalet/Biotech Research and Innovation Centre (BRIC), University of Copenhagen , Copenhagen, Denmark.ORCID 0000-0003-1833-3922
Karina SilinaInstitute of Pharmaceutical Sciences, ETH Zurich , Zurich, Switzerland.ORCID 0000-0003-3947-2710
Daniel F LeglerInstitute of Cell Biology and Immunology Thurgau (BITG) at the University of Konstanz , Kreuzlingen, Switzerland.ORCID 0000-0001-8610-4764
Cornelia HalinInstitute of Pharmaceutical Sciences, ETH Zurich , Zurich, Switzerland.ORCID 0000-0002-7899-2850

Funding

Danish Cancer Society R146-A9326-16-S2Danish Cancer Society R231-A13820Danish Cancer Society R368-A21555ETH Zurich XXXEuropean Regional Development Fund PID2022-137678OB-I00Generalitat Valenciana CIBEST/2024/66Novo Nordisk Foundation NNF19OC0058603Novo Nordisk Foundation NNF22OC0080995Ramón y Cajal Program RYC2021-034540-ISpanish Ministry of Science and Innovation and Universities MCIN/AEI/10.13039/501100011033Swiss National Science Foundation 189144Swiss National Science Foundation 220205
6 · The paper itself

Abstract

Dendritic cell (DC) migration via afferent lymphatics to draining LNs (dLNs) occurs in distinct steps that require the chemokine C-C motif ligand 21 (CCL21). In addition to full-length CCL21, which forms an immobilized perilymphatic gradient, a truncated soluble variant with enhanced gradient-forming capacity (CCL21-ΔC) was recently identified in tissues. We show that in skin, plasmin is continuously activated in a urokinase plasminogen activator (uPA)-dependent manner on lymphatic endothelial cells (LECs) and cleaves full-length CCL21, generating CCL21-ΔC. Inflammatory conditions, while promoting overall DC migration, markedly enhance this process, reducing immobilized perilymphatic CCL21 and increasing dermal CCL21-ΔC levels. Inhibition of uPA-mediated CCL21 cleavage causes full-length CCL21 to accumulate around dermal lymphatics, while CCL21-ΔC levels decline in the skin and dLN subcapsular sinus. Consequently, DC entry into afferent lymphatics is diminished, whereas DC egress from the subcapsular sinus into the LN parenchyma is enhanced. These findings reveal uPA/plasmin-dependent regulation of lymphatic CCL21 gradients and identify CCL21-ΔC as critical for DC migration.

Indexed as

Cell MovementChemokine CCL21Dendritic CellsUrokinase-Type Plasminogen ActivatorAnimalsEndothelial CellsLymphatic VesselsLymph NodesMiceMice, Inbred C57BLSkinChemokine CCL21Urokinase-Type Plasminogen Activator

Identifiers

PMID41591762
PMCPMC12839967

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.